CD16⁺ monocytes give rise to CD103⁺RALDH2⁺TCF4⁺ dendritic cells with unique transcriptional and immunological features

Vanessa Sue Wacleche,1,2 Amélie Cattin,1,2 Jean-Philippe Goulet,3 Dominique Gauchat,2 Annie Gosselin,2 Aurélie Cleret-Buhot,2 Yuwei Zhang,1,2 Cécile L. Tremblay,1,2 Jean-Pierre Routy,4,5 and Petronela Ancuta1,2

1Département de microbiologie, infectiologie et immunologie, Faculté de Médecine, Université de Montréal, Montreal, QC, Canada; 2Centre de recherche du Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada; 3Caprion Biosciences Inc., Montreal, QC, Canada; and 4Chronic Viral Illness Service and Research Institute and 5Division of Hematology, McGill University Health Centre, Montreal, QC, Canada

Key Points
- Human blood CD16⁺ and CD16⁻ MDDCs exhibit unique ITGAE/CD103⁺RALDH2⁺TCF4⁺ and CDH1/E-cadherin⁺ phenotypes, respectively.
- CD16⁺ monocytes preserve a unique transcriptional signature during differentiation into DCs, including the LPS-induced TNF production.

Classical CD16⁻ vs intermediate/nonclassical CD16⁺ monocytes differ in their homing potential and biological functions, but whether they differentiate into dendritic cells (DCs) with distinct contributions to immunity against bacterial/viral pathogens remains poorly investigated. Here, we employed a systems biology approach to identify clinically relevant differences between CD16⁺ and CD16⁻ monocyte-derived DCs (MDDCs). Although both CD16⁺ and CD16⁻ MDDCs acquire classical immature/mature DC markers in vitro, genome-wide transcriptional profiling revealed unique molecular signatures for CD16⁺ MDDCs, including adhesion molecules (ITGAE/CD103), transcription factors (TCF7L2/TCF4), and enzymes (ALDH1A2/RALDH2), whereas CD16⁻ MDDCs exhibit a CDH1/E-cadherin⁺ phenotype. Of note, lipopolysaccharides (LPS) upregulated distinct transcripts in CD16⁺ (eg, CCL8, SIGLEC1, MIR4439, SCIN, interleukin [IL]-7R, PLTP, tumor necrosis factor [TNF]) and CD16⁻ MDDCs (eg, MMP10, MMP1, TGM2, IL-1A, TNFRSF11A, lysosomal-associated membrane protein 1, MMP8). Also, unique sets of HIV-modulated genes were identified in the 2 subsets. Further gene set enrichment analysis identified canonical pathways that pointed to “inflammation” as the major feature of CD16⁺ MDDCs at immature stage and on LPS/HIV exposure. Finally, functional validations and meta-analysis comparing the transcriptome of monocyte and MDDC subsets revealed that CD16⁺ vs CD16⁻ monocytes preserved their superior ability to produce TNF-α and CCL22, as well as other sets of transcripts (eg, TCF4), during differentiation into DC. These results provide evidence that monocyte subsets are transcriptionally imprinted/programmed with specific differentiation fates, with intermediate/nonclassical CD16⁺ monocytes being precursors for pro-inflammatory CD103⁺RALDH2⁺TCF4⁺ DCs that may play key roles in mucosal immunity homeostasis/pathogenesis. Thus, alterations in the CD16⁺/CD16⁻ monocyte ratios during pathological conditions may dramatically influence the quality of MDDC-mediated immunity.

Introduction

Peripheral blood monocytes are myeloid cells originating from the bone marrow that infiltrate secondary lymphoid organs and peripheral tissues after a few hours/days of circulation through the blood.1,2 Monocytes contribute to tissue homeostasis and innate/adaptive immunity against pathogens, especially upon differentiation into dendritic cells (DCs) or macrophages (MΦ).3-13 In the intestine,
the majority of DCs and MΦ are derived from blood monocytes.\textsuperscript{4,14} In other tissues, monocyte-derived myeloid cells coexist with self-renewing tissue-resident MΦ of embryonic/fetal origin.\textsuperscript{15,16} The proportion between these 2 pools varies from homeostasis to tissue injury and during aging.\textsuperscript{17} Insights into the existence of self-renewing tissue-resident myeloid cells were mainly provided by studies in mice models,\textsuperscript{18-20} with evidence in humans being still scarce.\textsuperscript{21}

Human monocytes are classified into 3 major subsets according to their differential expression of CD14 and CD16: classical CD14\textsuperscript{++}, CD16\textsuperscript{-}, intermediate CD14\textsuperscript{+}CD16\textsuperscript{+}, and nonclassical CD14\textsuperscript{+}CD16\textsuperscript{-} monocytes.\textsuperscript{22} Further, other surface markers such as Slan/M-DC8 proved useful to distinguish classical vs intermediate/nonclassical monocytes.\textsuperscript{23-26} Multiple transcriptional studies support the existence of a developmental relationship between these blood monocyte subsets.\textsuperscript{26-29} Most recently, deuterium labeling in humans and complementary studies in humanized mice models demonstrated the sequential differentiation of bone marrow-derived classical monocytes into intermediate and nonclassical monocytes.\textsuperscript{2} The identification of CCR2 and CX3CR1 as chemokine receptors involved in the tissue-specific homing of classical and intermediate/nonclassical monocytes, respectively, in humans and mice\textsuperscript{30,31} open the path for a detailed understanding of the distinct roles played by these monocytes in tissue homeostasis and disease pathogenesis.\textsuperscript{4,13,32-35} Briefly, intermediate/nonclassical monocytes distinguish from classical monocytes by their increased frequency during various pathological conditions, as well as their ability to produce pro-inflammatory cytokines such as tumor necrosis factor (TNF)-α and interleukin (IL)-1\textsuperscript{2,23,33,36-41} to maintain blood vessel homeostasis (“patrolling” CX3CR1\textsuperscript{-} monocytes),\textsuperscript{36} and to sense viruses via TLR7/TLR8.\textsuperscript{3,35,42} Given that monocytes are DC precursors,\textsuperscript{3,13} these findings raise new questions relative to potential functional differences between classical and intermediate/nonclassical monocyte-derived DCs (MDDCs). Although both CD16\textsuperscript{-} and CD16\textsuperscript{+} monocytes differentiate into DCs in the presence of granulocyte-MΦ colony-stimulating factor (GM-CSF) and IL-4 in vitro,\textsuperscript{33,43} CD16\textsuperscript{-} monocytes were reported to preferentially acquire DC features in a model of trans endothelial migration.\textsuperscript{35} Also, CD16\textsuperscript{-} is distinguished from CD16\textsuperscript{+} MDDCs by their cytokine production, expression of costulatory molecules, trafficking potential, and antigen presentation capacity.\textsuperscript{42,46} At steady state, it was reported that monocytes can traffic into tissues where they capture antigens while retaining their “monocyte” phenotype.\textsuperscript{34,49} Whether such tissue-infiltrating monocytes return in the blood circulation remains a yet unproved possibility.\textsuperscript{50} The latter scenario may explain the transcriptional and functional heterogeneity of CD16\textsuperscript{-}/CD16\textsuperscript{+} monocyte subsets in the blood, indicative of different stages of monocyte differentiation.\textsuperscript{26-29}

In this study, we used a systems biology approach to explore features of CD16\textsuperscript{+} and CD16\textsuperscript{-} MDDCs. Our results support a model in which CD16\textsuperscript{+} and CD16\textsuperscript{-} monocytes are imprinted/programmed to give rise to transcriptionally distinct MDDC subsets that may play different roles in tolerance vs immunity. Of particular importance, our study reveals that CD16\textsuperscript{+} vs CD16\textsuperscript{-} MDDCs express unique adhesion molecules (eg, CD103), enzymes (eg, RALDH2), and transcription factors (eg, transcription factor 4 [TCF4]), typically expressed by mucosal DCs, supporting a scenario in which CD16\textsuperscript{-} monocytes are precursors for mucosal DCs. These insights orient the rational use of CD16\textsuperscript{-} vs CD16\textsuperscript{+} monocytes in DC-based immunotherapies.

## Material and methods

### Study subjects

Healthy HIV-uninfected donors were recruited at the Montreal Chest Institute, McGill University Health Centre and Centre Hospitalier de l’Université de Montréal (CHUM, Montreal, QC, Canada). Large quantities of peripheral blood mononuclear cells (PBMCs) (10\textsuperscript{9}-10\textsuperscript{10} cells) were collected by leukapheresis, as previously described.\textsuperscript{51} Cytomegalovirus infection was determined on detection of cytomegalovirus-specific antibodies (Abs), using chemiluminescent microparticle immunoassay.\textsuperscript{52}

### Ethics statement

This study, using PBMC samples from healthy HIV-uninfected subjects, was conducted in compliance with the principles included in the Declaration of Helsinki. This study received approval from the Institutional Review Board of the McGill University Health Centre and the CHUM-Research Centre, Montreal, Quebec, Canada. Written informed consents were obtained from all study participants.

### Flow cytometry phenotypic analysis

Surface staining was performed as previously described,\textsuperscript{53} with the following fluoroochrome-conjugated Abs: CD3 FITC (Becton Dickinson, San Jose, CA); CD14 PE (Becton Dickinson, San Jose, CA); CD1a PE-Cy5 (BD Pharmingen, San Diego, CA); and CD16 PE-Cy7 (BD Pharmingen, San Diego, CA); and CD16 PE-Cy5 (BD Pharmingen, San Diego, CA); CD1a PE-Cy7 (BD Pharmingen, San Diego, CA); and CD16 PE-Cy5 (BD Pharmingen, San Diego, CA). Cells were analyzed using a LSRII cytometer, Diva (BD Biosciences, San Jose, CA). Positivity gates were placed using fluorescence minus 1.\textsuperscript{53,54}

### Magnetic and fluorescence-activated cell sorting

Total monocytes were isolated from PBMCs of HIV-uninfected subjects by negative selection, using magnetic beads (MACS; Miltenyi).\textsuperscript{26} Monocytes were further stained with a cocktail of CD1c, CD3, CD8, CD19, and CD56 Abs for fluorescence-activated cell sorting (FACS). Of note, CD14 Abs were not included in the sorting cocktail in an effort to avoid any potential stimulation via CD14.\textsuperscript{55} The CD16\textsuperscript{+} (including mainly nonclassical CD14\textsuperscript{-}CD16\textsuperscript{+} monocytes) and CD16\textsuperscript{-} monocytes, lacking expression of the lineage markers CD3, CD8, CD19, CD56, and CD1c, were sorted by FACS (BD Aria II; BD Biosciences; low pressure [20 PSI], 100 μM nozzle). Postsort quality control analysis indicated purities greater than 96% (supplemental Figure 1).

### Generation of immature and mature MDDCs

Monocyte subsets were differentiated into DCs by culture in RPMI 1640 media (2% fetal bovine serum; 1% penicillin/streptomycin) containing GM-CSF and IL-4 (20 ng/mL; R& D Systems) for 6 days; cytokine-containing media were refreshed every 2 days (Figure 1A). For phenotypic analysis, MDDC maturation was induced by stimulation with Escherichia coli lipopolysaccharides (LPS; Sigma; 100 ng/mL) for 48 hours. Immature and mature MDDCs were stained with Abs against CD14 (monocyte marker), CD1a, CD1c,
and DC-SIGN (immature MDDC markers), and CD83 and CCR7 (mature MDDC markers).

Confocal microscopy

The visualization of MDDC phenotype and morphology was performed by confocal microscopy, as previously described.56,57 Briefly, MDDCs were stained with mouse anti-human PE-conjugated CD1a Abs (BD Pharmingen) and Phalloidin-AF488 (Invitrogen). Epi-fluorescent and Spinning Disc confocal microscopy images were acquired out on an automated Cell Observer Z1 microscope (Carl Zeiss), using the AxioVision 4.8.2 software (Carl Zeiss).

Genome-wide transcriptional profiling

Matched CD16+ and CD16− MDDCs were generated from 5 different healthy HIV-uninfected donors and exposed to media, E. coli LPS (100 ng/mL), or infectious NL4.3Bal HIV-1 virions (50 ng HIV-p24/10⁶ MDDC) for 24 hours. The HIV NL4.3Bal molecular clone plasmid was a gift from Dana Gabuzda (Dana-Farber Cancer Institute, Boston, MA). HIV viral stocks were prepared by infection of 293T cells with the appropriate plasmid; the concentration of HIV stocks was determined by ELISA quantification of HIV-p24 protein; and HIV infectivity was titrated on primary CD4+ T cells, as previously described.57-60 Total RNA was isolated using RNeasy columns kit (Qiagen). RNA quantity was determined by Pearl NanoPhotometer (Implen, Germany; 1-5 μg RNA/10⁶ cells). Genome-wide analysis of gene expression was performed by Génome Québec Innovation Centre (Montreal, QC, Canada), using the Affymetrix ST 2.0 chips, covering more than 53 000 transcripts and known splice variants across the human transcriptome. Gene expression data were normalized using the robust multiarray average method, as implemented in the oligo Bioconductor package.60,61 Differentially expressed genes were adjusted using Benjamini-Hochberg method for multiple hypotheses testing, as we previously reported.57-59 This allowed the use of false discovery rate thresholds to assess whether a gene is differentially expressed or not. Differentially expressed genes were further identified (cutoff 1.3-fold; P < .05; adjusted [adj.] P < .05) and classified through gene ontology (GO), using the Affymetrix web-based application (Affymetrix), whereas differentially expressed pathways were identified using Ingenuity pathway analysis, gene set variation analysis,62 and gene set enrichment analysis,63 as previously described by our group.64 Corresponding heat maps for biological function categories were generated using programming language R.65 The clustering was performed using the complete linkage method on the Euclidean distances from the values represented in the heat maps, as we previously described.56-59 Although these methods are known to be "unsupervised," clustering samples with a subset of differentially expressed genes are considered as "supervised."

Real-time reverse transcription polymerase chain reaction quantification

One-step SYBR Green real-time reverse transcription polymerase chain reaction (RT-PCR) was carried out in a LightCycler 480 II (Roche), using Qiagen reagents according to manufacturer’s recommendations, as previously described.56 Briefly, human ITGAE/CD103, CDH1/E-cadherin; ALDH1A2/RALDH2, TCF7L2/TCF4, IGSF2/CD101, and SIGLEC1/CD169 primers were purchased from Qiagen (QuantiTect Primer Assay). The expression of each gene was normalized relative to the internal control 28S rRNA levels (forward 5’-CGGAGATCTTGTCGCCACTA-3’; reverse 5’-GGGGACACCTCCATTCTTA-3’).58 Each RT-PCR reaction was performed in 2 to 3 replicates. 

Cytokine and chemokine quantification

Levels of TNF-α, CCL22, and CCL18 in cell culture supernatants were quantified by ELISA (R&D Systems), according to the manufacturer’s protocol.

Statistics

Statistical analyses were performed using the GraphPad Prism 6. Details are included in figure legends. Sample size calculations for microarray studies and other investigations were based on previous results.26,53,56,64,65

Accession numbers

The entire microarray dataset and technical information requested by Minimum Information About a Microarray Experiment are available at the Gene Expression Omnibus database under accession number GSE111474.

Results

Peripheral blood CD16+ and CD16− monocytes acquire typical DC features in vitro

Phenotypic features of CD16+ and CD16− MDDCs were first investigated before/after LPS-induced maturation. Highly pure CD16+ and CD16− monocytes were cultured in the presence of GM-CSF and IL-4 for 6 days (Figure 1A; supplemental Figure 1). Both CD16+ and CD16− monocytes differentiate into DCs, as reflected by high levels of CD1c and HLA-DR and the loss of CD16 expression, with CD16 expression conserved on a fraction of CD16− MDDCs (Figure 1B-C). Further, the expression of immature (CD1a, CD1c, DC-SIGN) vs mature (CD83, CCR7) DC markers was assessed on these MDDC subsets before and after LPS-induced maturation. Both CD16+ and CD16− MDDCs expressed similarly high levels of CD1c, CD1a and DC-SIGN at immature stage, and the mature DC markers CD83 and CCR7 upon LPS exposure (supplemental Figure 2A-B). Staining with CD1a Abs and phalloidin (actin filaments) followed by confocal microscopy visualization demonstrated that both MDDC subsets acquired a typical veiled morphology, with a tendency for more protrusions/filopodia on the surface of CD16− MDDCs (supplemental Figure 2C). Thus, both CD16+ and CD16− monocytes differentiate into DCs expressing classical immature/mature DC markers and typical veiled morphology.

CD16+ and CD16− MDDCs respond differently to bacterial vs viral antigens

To determine whether the distinct ability of CD16+ vs CD16− monocytes to sense bacterial/viral pathogens3,42 is inherited by their DC progeny, genome-wide transcriptional profiles of CD16− and CD16+ MDDCs were analyzed before/after exposure to LPS or infectious HIV-1 (Figure 1A,D-H; supplemental Figure 3). Of note, the HIV concentration used (ie, 50 ng/mL HIV-p24) was selected in preliminary experiments as being optimal in terms of efficient HIV trans infection from MDDCs to CD4+ T cells (data not shown). Differentially expressed probe sets were identified based on P values.
Figure 1.

A Experimental flow chart

FACS Analysis
Genome-wide transcriptional profiling (Affymetrix HG Plus 2.0 Microarrays)
RT-PCR and ELISA validations

B Blood monocytes

C MDDC

D Immature MDDC

E LPS-exposed MDDC

F LPS-exposed MDDC

G HIV-exposed MDDC

H HIV-exposed MDDC
(P < .05), adjusted P values (adj. P < .05), and fold change (FC) expression ratios (Figure 1D-H; supplemental Tables 1-8). A total of 3374 probe sets were differentially expressed between CD16\(^+\) and CD16\(^-\) MDDCs at immature stage (Figure 1D). Upon LPS-induced maturation, 9014 and 9167 probe sets were regulated in CD16\(^+\) and CD16\(^-\) MDDCs, respectively (P < .05; Figure 1E). Among LPS-modulated probe sets, 7041 and 663 probe sets were preferentially expressed in immature CD16\(^+\) and CD16\(^-\) MDDCs, respectively (Figure 1F). In contrast to the high number of LPS-modulated genes, only 1164 and 663 probe sets were modulated by HIV in CD16\(^+\) and CD16\(^-\) MDDCs, respectively (P < .05; Figure 1G), with 36 commonly HIV-modulated transcripts (Figure 1H). These results demonstrate that CD16\(^+\) and CD16\(^-\) monocytes are precursors for transcriptionally distinct MDDC subsets able to sense bacterial/viral pathogens in unique manners.

**Distinct transcriptional profiles in CD16\(^+\) and CD16\(^-\) MDDCs at immature stage**

Based on P values (<.05) and FC expression ratios (cutoff, 1.3), 447 and 692 probe sets were preferentially expressed in immature CD16\(^+\) and CD16\(^-\) MDDCs, respectively (data not shown). When adj. P < .05 were applied, 159 and 288 probe sets were found preferentially expressed in immature CD16\(^+\) and CD16\(^-\) MDDCs, respectively; new molecular markers for CD16\(^+\) MDDCs and CD16\(^-\) MDDCs were identified (supplemental Tables 1 and 2).

Gene set variation analysis of differentially expressed genes identified canonical pathways (C2) and biological processes (C5) preferentially associated with CD16\(^+\) or CD16\(^-\) MDDCs (supplemental Figure 4A). Among C2 canonical pathways, pathways enriched in CD16\(^+\) MDDCs were linked to nuclear receptors and T-helper pathways, as well as regulation of interferon (IFN) pathway; whereas pathways enriched in CD16\(^-\) MDDCs were linked to DNA replication and repair and telomere maintenance (supplemental Figure 4A-B). Among C5 biological processes, pathways enriched in CD16\(^+\) MDDCs were linked to actin filament, response to extracellular stimuli, IFN-γ production, positive regulation of MAPKKK cascade, lymphocyte differentiation, regulation of lymphocyte activation, positive regulation of T-cell activation, B-cell activation, and lymphocyte activation (supplemental Figure 4B). In contrast, biological processes enriched in CD16\(^-\) MDDCs included nucleus and endonuclease activity, cell cycle, DNA replication, chromatin, and microtubule motor activity (supplemental Figure 4B).

Further GO classification of differentially expressed genes in CD16\(^+\) and CD16\(^-\) MDDCs revealed transcripts related to different biological functions, including: transcription factors, cytokines, adhesion molecules, chemotaxis, and cell projections (Figure 2). For the GO term transcription factors, transcripts enriched in CD16\(^+\) MDDCs included the myocyte enhancer factor 2, polycomb group ring finger 2, peroxisome proliferator-activated receptor γ, transcription factor 7-like 2 (TCF7L2 or TCF4), basic helix-loop-helix family member e41, forkhead box O1 (FOXO1), homeodomain interacting protein kinase 2, and activating transcription factor 3, whereas transcription factors enriched in CD16\(^-\) MDDCs included E2F transcription factor 6 (E2F6) and the hypoxia inducible factor 1, α subunit (HIF1A; Figure 2A). The heat map in Figure 2A also reveals upregulation of transcripts for the stem cell surface markers CD34 and c-kit in CD16\(^+\) vs CD16\(^-\) MDDCs. For the GO term cytokines, JAK1, CCL2, IL-21R, PTGER4, IL-15, TNFSF14, CD86, SERPINA1, and aldehyde dehydrogenase 1 family member A2 (ALDH1A2 or retinaldehyde dehydrogenase 2 [RALDH2]) transcripts were enriched in CD16\(^+\) MDDCs, whereas IL1RL2, dual oxidase 1 (DUOX1), interferon α-inducible protein 6 (IFI16), IL17RB, and CCL18 were enriched in CD16\(^-\) MDDCs (Figure 2B). For the GO term adhesion molecules, CD16\(^+\) MDDCs were enriched in CD97, signaling lymphocytic activation molecule family 7, TNFRSF12A, ITGAL, paladin, RAPH1, ALCAM, LY9, and ITGAE (or CD103) transcripts, whereas C-type lectin domain family 4, member M; integrin, α 9; SIGLEC1; CDH1 (or E-cadherin); ADAM23; CDH2; EPCAM; SELL; c-kit; CD34; and IFT74 transcripts were upregulated in CD16\(^-\) MDDCs (Figure 2C). The GO term chemotaxis further revealed preferential expression of CCR6 in CD16\(^+\) MDDCs (Figure 2D). Finally, several transcripts associated with the GO term cell projections were differentially expressed in CD16\(^+\) vs CD16\(^-\) MDDCs (Figure 2E).

**Transcripts differentially modulated by LPS in CD16\(^+\) vs CD16\(^-\) MDDC**

Large sets of transcripts were modulated by LPS in both CD16\(^+\) and CD16\(^-\) MDDCs (Figure 1E-F). Nevertheless, unique transcriptional signatures induced by LPS were identified in each MDDC subset (Figure 3A; supplemental Figures 3 and 5). Using adj. P < .05 and FC cutoff 1.3 selection criteria, 261 and 221 transcripts were found upregulated and downregulated, respectively, after LPS exposure uniquely in CD16\(^+\) MDDCs (supplemental Tables 3 and 4), whereas 285 and 467 transcripts were upregulated and downregulated, respectively, by LPS preferentially in CD16\(^-\) MDDCs (supplemental Tables 5 and 6). Among transcripts specifically modulated by LPS in CD16\(^+\) MDDCs, CCL8, SIGLEC1, microRNA (MIR)-4439, SCIN, IL7R, PLTP, TNF, CFP (properdin, the positive regulator of the alternative pathway of complement activation), IL25, IL-28B, IL-28A, and IL-4 were differentially expressed in CD16\(^+\) vs CD16\(^-\) MDDCs (Figure 3B).
Figure 2. Gene ontology classification of differentially expressed genes in immature CD16\(^{+}\) and CD16\(^{-}\) MDDCs. Transcriptional profiling was performed as described in Figure 1A.D. Differentially expressed genes in CD16\(^{+}\) (green) vs CD16\(^{-}\) (blue) MDDCs exposed to media (immature; \(P < .05; FC\) cutoff, 1.3) were classified using gene ontology in (A) transcription factors, (B) cytokines, (C) adhesion molecules, (D) chemotaxis, and (E) cell projections. Each heatmap column represents data from a distinct donor for matched immature CD16\(^{+}\) vs CD16\(^{-}\) MDDCs (\(n = 5\)).
Figure 3. Differential gene expression in CD16\textsuperscript{+} and CD16\textsuperscript{−} MDDCs in response to LPS. Transcriptional profiling was performed as described in Figure 1A,E-F with matched MDDC subsets exposed to media (immature) or LPS (mature) for 24 hours. Shown are top-regulated genes in immature and mature CD16\textsuperscript{+} compared with CD16\textsuperscript{−} MDDCs (A) and differentially expressed genes in CD16\textsuperscript{+} vs CD16\textsuperscript{−} MDDC subsets exposed to LPS (P < .05; FC cutoff, 1.3) linked to the gene ontology terms chemotaxis (B) and cytokines (C). Heat map cells are scaled by the expression level z-scores for each probe individually. Results were generated with cells from 5 different donors identified with different color codes.
Figure 4.

A HIV: top modulated genes

B HIV: exosomes
ABCA1, ITGAV, KLF10, and FCGR3A were downregulated (supplemental Tables 3 and 4). Among transcripts specifically modulated by LPS in CD16<sup>+</sup> MDDCs, upregulated were matrix metalloproteinase 10 (stromelysin 2, MMP10), MMP1, TNFRSF1F1A, IL-1A, lysosomal-associated membrane protein 1, MMP8, fibrillin 1, aldehyde dehydrogenase 1 family member L2 (ALDH1L2), IL-1 receptor antagonist, triggering receptor expressed on myeloid cells 1, and mucosa-associated lymphoid tissue lymphoma translocation gene 1 (MALT1), whereas CD24; STEAP family member 4; CD163 molecule-like 1(CD163L1); MIR146B; and myeloperoxidase transcripts were downregulated (supplemental Tables 5 and 6).

GO classification of differentially expressed genes in CD16<sup>+</sup> and CD16<sup>-</sup> MDDCs exposed to LPS revealed transcripts linked to cell migration and cytokines. For the GO term chemotaxis, top-upregulated transcripts included OR1D2, TNFRSF11A, RALA, CXCR4, and CCL18 for CD16<sup>-</sup> MDDCs, and AMICA1; chemerin chemokine-like receptor 1; ITGAM; protein tyrosine phosphatase; receptor type, J; CCL22; and proteolipid protein 2 for CD16<sup>+</sup> MDDCs (Figure 3B). For the GO term cytokines, top regulated transcript enriched in CD16<sup>-</sup> MDDCs included fms-related tyrosine kinase 3, MALT1, NUP107, IGF1R, CXCR4, IL17RB, CCL18, EGR1, IL-7, IL-23R, IFNA1, and IL-1R1, whereas in CD16<sup>+</sup> MDDCs, MIRs included IL-21R, LTB, IL-18, LTA, CCL22, TNF, MYD88, interferon α-inducible protein 6, CD86, and DUOX2 (Figure 3C). Thus, both MDDC subsets sense LPS, but in transcriptionally distinct manners, with CD16<sup>-</sup> compared with CD16<sup>+</sup> MDDCs exhibiting a superior pro-inflammatory profile, as reflected by their upregulated expression of LTβ, IL-18, LTA, TNF, CCL22, MYD88, and DUOX2 transcripts.

Transcripts differentially modulated by HIV in CD16<sup>+</sup> vs CD16<sup>-</sup> MDDCs

Transcriptional changes observed in CD16<sup>+</sup> or CD16<sup>-</sup> MDDCs on exposure to HIV were minor compared with those induced by LPS (Figure 1D-H; supplemental Figures 3 and 6). A number of 44 and 84 transcripts were specifically up- and downregulated, respectively, by HIV in CD16<sup>-</sup> MDDCs (supplemental Table 7). Also, a number of 25 and 30 transcripts were specifically up- and downregulated, respectively, by HIV in CD16<sup>+</sup> MDDCs (P < .05; FC cutoff 1.3; supplemental Table 8). Heat maps in supplemental Figure 6A-B illustrate top transcripts modulated by HIV in CD16<sup>+</sup> and CD16<sup>-</sup> MDDCs (P < .05; FC cutoff, 1.3). None of these changes in gene expression reached an adj. P < .05 (supplemental Figure 3). Of note, HIV differentially regulated the expression of multiple MIRs in both CD16<sup>+</sup> and CD16<sup>-</sup> MDDCs. Transcripts upregulated by HIV in CD16<sup>-</sup> MDDCs included the IFI6, MIR568, MIR4718, CD101 (a molecule potentially involved in the negative regulation of T-cell activation<sup>86</sup>), MIR4717, SIGLEC1, MIR3692, MIR3188, MIR4441, Kruppel-like factor 10 (KLF10), MIR4672, MIR5485, CASP6, MIR583, and MIR4491, whereas downregulated transcripts included the p-associated, coiled-coil containing protein kinase 1 pseudogene 1 (ROCK1P1), ubiquitin-specific peptidase 17-like family member 5, cytokine receptor-like factor 2, MIR5483, MIR509-3, IFNA1, fms-related tyrosine kinase 3, IL-2RA, mediator complex subunit 27, activating transcription factor 3, IFNA16, and CCR4 (Figure 4A; supplemental Table 7; supplemental Figure 6A). Transcripts upregulated by HIV in CD16<sup>-</sup> MDDCs included MIR1271, MIR516A2, MIR3911, MIR196A1, S100B, MIR320C1, MIR3665, MIR3201, and MIR523; whereas downregulated transcripts included MIR4499, MIR3975, MIR4263, MIR545, MIR130B, and MIR4308 (Figure 4A; supplemental Table 8; supplemental Figure 6B). Of note, immature CD16<sup>-</sup> MDDCs shared transcripts with HIV-exposed CD16<sup>-</sup> MDDCs (Figure 4A). When GO analysis was performed, transcripts associated to exosomes were predominating and preferentially expressed by HIV-exposed CD16<sup>-</sup> vs CD16<sup>-</sup> MDDCs.

CD16<sup>-</sup> MDDCs exhibit a unique pro-inflammatory molecular signature

Gene set enrichment analysis identified canonical pathways modulated in CD16<sup>-</sup> vs CD16<sup>-</sup> MDDCs by LPS and/or HIV exposure (Figure 5). Canonical pathways linked to 20S proteasome, myeloid lineage, myeloid M<sub>0</sub> DC inflammatory interleukin, and inflammation II were enriched in CD16<sup>-</sup> vs CD16<sup>-</sup> MDDCs in all experimental conditions (Figure 5A). Changes in the expression of various MIRs were also observed, including the preferential expression in CD16<sup>-</sup> vs CD16<sup>-</sup> MDDCs of MIR1271 under constitutive conditions, MIR146b on LPS stimulation, and MIR4499 after HIV exposure (Figure 5B). Thus, distinct canonical pathways and MIR-mediated regulatory mechanisms control MDDC functions, with inflammation being a key feature of CD16<sup>-</sup> MDDCs.

CD16<sup>+</sup> monocytes differentiate into CD103<sup>+</sup>RALDH2<sup>+</sup> TCF4<sup>+</sup> DCs that produce high TNF levels

The microarray results listed in supplemental Tables 1-8 and illustrated in supplemental Figure 7 were further subject to RT-PCR and ELISA validations. Results in Figure 6A reveal that CD103, RALDH2, and TCF4 are indeed transcriptional markers for immature CD16<sup>+</sup> MDDCs, whereas CD16<sup>-</sup> MDDCs exhibited preferential CD1H/E-cadherin transcripts. RT-PCR validations also revealed that HIV-exposed CD16<sup>+</sup> and CD16<sup>-</sup> MDDCs are distinguished by preferential expression of CD101 and CD169, respectively (Figure 6B). Finally, results in Figure 6C illustrate that CD16<sup>+</sup> vs CD16<sup>-</sup> MDDCs produce higher levels of TNF-α on LPS exposure. Also, CD16<sup>+</sup> vs CD16<sup>-</sup> MDDCs produced superior levels of CCL22 at immature stage or on HIV exposure, whereas CCL18 was mainly produced by immature and mature CD16<sup>-</sup> MDDCs (Figure 6C). In contrast to HIV that did not increase the ability of MDDC subsets to produce these...
Figure 5. CD16\(^+\) and CD16\(^-\) MDDCs exposed to media, LPS, or HIV exhibit unique molecular signatures. Genome-wide transcriptional profiles were generated as described in Figure 1A,D-H for MDDC subsets exposed to media, LPS, or HIV for 24 hours. (A) Gene set enrichment analysis allowed the identification of top-regulated canonical pathways (C2), commonly and differentially expressed between CD16\(^+\) vs CD16\(^-\) MDDCs exposed to media, LPS, or infectious HIV virions. Results were generated with matched MDDC subsets from 5 different donors.

(B) Shown are top-regulated micro-RNAs (MIR) differentially expressed between CD16\(^+\) and CD16\(^-\) MDDCs exposed to media, LPS, or infectious HIV virions. Results were generated with matched MDDC subsets from 5 different donors.
cytokines/chemokines, LPS was a strong inducer of TNF-α and CCL22, but not CCL18 (Figure 6C). Thus, CD16+ monocytes are precursors for CD103+ RALDH2+ TCF4+ DCs with a superior pro-inflammatory and chemoattractant potential compared with CD16+ MDDCs that express a CD1H+ transcriptional signature.

Figure 6. Novel functional markers for CD16+ and CD16- MDDCs. MDDC subsets were generated and exposed to media (immature), LPS (mature), or HIV for 24 hours, as described in Figure 1A. Shown are real-time RT-PCR validation of relative ITGAE/CD103, CDH1/E-cadherin, ALDH1A2/RALDH2, and TCF7L2/TCF4 mRNA expression in immature MDDC subsets (A), as well as IGSF2/CD101 and SIGLEC1/CD169 in HIV-exposed MDDC subsets (B). (A-B) Results were generated with matched MDDC subsets from 3 to 5 different donors. Each symbol represents the median value of 2 to 3 RT-PCR replicates, with values for CD16- MDDCs being considered 1. Paired Student t test P values are indicated on the graphs. (C) Shown are levels of TNF-α, CCL22, and CCL18 quantified by ELISA in cell culture supernatants from matched CD16+ and CD16- MDDCs on exposure to media, LPS, or HIV (n = 4-5, mean ± SEM). Paired Student t test P values for log10 cytokine levels are indicated on the graphs.
A conserved transcriptional signature in CD16<sup>+</sup> monocytes and MDDCs

A meta-analysis was performed using transcripts differentially expressed in CD16<sup>+</sup> vs CD16<sup>−</sup> monocytes (GSE16836<sup>26</sup>) and CD16<sup>+</sup> vs CD16<sup>−</sup> MDDCs (GSE111474, current manuscript) to identify a transcriptional signature preserved during monocyte differentiation into DCs. Results in Figure 7 reveal multiple transcripts conserved between CD16<sup>+</sup> MDDCs and their monocyte progenitors. This indicates that CD16<sup>+</sup> monocytes are stably imprinted with a transcriptional profile that is conserved during differentiation into DCs.

Discussion

Monocytes are precursors for DCs, professional antigen-presenting cells that shape self-tolerance as well as immunity to pathogens. Here, we provide evidence that intermediate/nonclassical CD16<sup>+</sup> and classical CD16<sup>−</sup> monocytes are precursors for transcriptionally/functionally distinct DC subsets (Figure 8) that may exhibit a peculiar capacity to shape immunity against bacterial/viral pathogens. Thus, a functional specialization exists not only between CD16<sup>+</sup> and CD16<sup>−</sup> monocytes<sup>3,5,22,42</sup> but also between their DC progeny, supporting the idea that changes in monocyte heterogeneity during various pathological conditions have consequences on the quality of DC-mediated immune responses.<sup>13</sup>

Biological processes linked to lymphocyte activation were enriched in CD16<sup>+</sup> vs CD16<sup>−</sup> MDDCs. Indeed, CD16<sup>−</sup> MDDCs expressed transcripts involved in immunological synapse formation, including activation molecules (CD86, CD97, LY9), adhesion molecules (ALCAM, LFA-1), and transcription factors (FOXO1, activating transcription factor 3, TCF4). CD97 was previously identified as a marker for CD16<sup>+</sup> monocytes<sup>26</sup> and an HIV permissiveness factor<sup>71</sup>; FOXO1 upregulates CCR7 and ICAM1 for complete DC maturation<sup>72</sup>; AFT3 has a role in Th17 polarization<sup>73</sup>; and TCF4, a component of the Wnt/β-catenin pathway, regulates DC functions<sup>74,75</sup> and restricts HIV in myeloid cells.<sup>76</sup> As opposed to CD16<sup>+</sup> MDDCs, transcriptional profiles in CD16<sup>−</sup> MDDCs point to a less active cellular metabolism, with enriched expression of early hematopoietic precursor and stem cell transcripts (CD34, c-kit, and
ITAG9, HiF1A), cell migration markers (CCR6, SELL and EPCAM), cytoskeleton (PAK7), adhesion molecules (CDH1 and CDH2) and phagocytosis (SIGLEC1). The biological processes enriched in CD16+ vs CD16− MDDCs included biological terms such as cell cycle, DNA replication, chromatin, and microtubule motor activity. CD16+ compared with CD16− MDDCs, were also enriched in transcripts involved in the protection against oxidative stress including myeloperoxidase, DUOX1, and DUOXA1. Interestingly, CD16− MDDCs also expressed the sensor for microbial DNA IFI16, previously reported to sense HIV in CD4+ T cells.79

Pioneering studies by Sánchez-Torres et al demonstrated that CD16+ vs CD16− MDDCs differ in their immunogenic potential,43 with differences in CD86 and CD11A expression that are confirmed by our transcriptional studies. One major finding of our study is that CD16+ and CD16− MDDCs exhibit unique CD103−/ITGAE CDH1/E-cadherin phenotypes, respectively. Our findings mirror evidence in mice demonstrating distinct roles of mucosal CD103+ and E-cadherin+ DCs in intestinal tolerance (Treg differentiation) and immunity (Th17 differentiation), respectively.80–82 RALDH2 is involved in the biosynthesis of the retinoic acid (RA) from vitamin A.83–85 The coexpression of CD16 with RALDH2 in CD16+ MDDCs expressed transcripts for inflammatory cytokines/chemokines (TNFα, IL-18, CXCL1), complement components (C2, CFP), phagocytosis and HIV capture (SIGLEC1),96 and microRNA (Mir-331, Mir-4439). In contrast, mature CD16+ MDDCs expressed transcripts associated with type-1 interferon response (IL1A, IFNA1), inflammasome activation pathway (MALT1,97,98), cell migration (CXCL6 and metalloproteinases MMP1, MMP8100 and MMP10101), Th17 polarization (IL-23, IL-6ST), DC-T-cell interaction (ALCAM, TNFRSF11), and mitochondrial functions (ALDH1H2). Thus, CD16+ and CD16− MDDCs respond differently to LPS, indicative of each DC subset exhibits a distinct immunological role in immunity.

In contrast to LPS, HIV exposure induced minimal changes in the transcriptional profile of both CD16+ and CD16− MDDCs, with no signs of DC maturation. Our results are in line with studies published by other groups demonstrating the limited capacity of MDDCs to sense HIV.102–105 Indeed, HIV was reported to inhibit the function of TANK-binding kinase 1, a kinase involved in IFN signaling pathway.106 Nevertheless, specific transcripts (ie, CD101 and SIGLEC1) and microRNAs were identified as differentially modulated by HIV in these MDDC subsets; their role in controlling the immunogenic vs
pathogenic features of CD16⁺ MDDCs during bacterial or viral infection remains to be investigated in future studies.

Previous transcriptional characterization of monocyte subsets and their progeny provided valuable insights into their functional specialization. In our study, canonical pathways linked to inflammation distinguished CD16⁺ from CD16⁻ MDDCs at immature stage, as well as after exposure to LPS or HIV. Noteworthy, similar to CD16⁺ monocytes, we demonstrate that CD16⁺ MDDCs are major TNF-α producers in response to LPS. Consistently, our meta-analysis revealed that transcripts differentially expressed in CD16⁺ vs CD16⁻ monocytes were also found in the present study as markers of immature CD16⁺ MDDCs (eg, TCF7L2) and CD16⁻ MDDCs (eg, HIF1α; Figure 7). Thus, CD16⁺ and CD16⁻ monocytes are imprinted with a unique transcriptional program, likely via epigenetic modifications, that is in part preserved during differentiation into DCs. This unique transcriptional imprinting/programming may be the result of distinct cell-to-cell and/or antigens/pathogens interactions during monocyte trafficking in vivo.

In this study, we did not distinguish between intermediate and nonclassical CD16⁺ monocytes. Future studies should use alternative markers such as M-DC8/slan23-25,41 to study the immunological features of DCs derived from these functionally distinct CD16⁺ monocyte subsets.

In conclusion, our results provide evidence supporting the existence of a “division of labor” between CD16⁺ and CD16⁻ MDDCs and offer a solid platform for future validations toward the identification of molecular determinants of DC immunogenicity/pathogenicity, with relevance for pathological conditions such as sepsis and HIV-1 infection (Figure 8). Alterations of the CD16⁺/CD16⁻ monocyte ratio may significantly influence the quality of DC-mediated immune responses in the context of specific pathogens; these aspects deserve future detailed investigations. Finally, our results provide guidance for the rational use of CD16⁺ vs CD16⁻ MDDCs in DC-based therapeutic strategies.

Acknowledgments

The authors thank the Centre de recherche du Centre Hospitalier de l’Université de Montréal FACS Core Facility for expert technical support in FACS analysis and cell sorting, Mario Legault (HIV/AIDS and Infectious Diseases Network of the Fonds de Recherche Québec-Santé) for help with ethical approvals and informed consents, and Dana Gabuzda (Dana-Farber Cancer Institute, Boston, MA) for the HIV molecular clones. The authors thank Josée Giroud and Angie Massicotte (McGill University Health Centre) for their involvement in human subject recruitment for leukapheresis collection, and Natalia Fonseca do Rosario and Laurence Raymond Marchand for assay optimization, contribution to cell sorting and culture, and critical reading of the manuscript. Lastly, the authors acknowledge the major contribution to this work of all human donors via their gift of leukapheresis.

This work was supported by grants from the Canadian Institutes of Health Research (CIHR; HOP-120239) (P.A.) and by Canadian HIV Cure Enterprise Team Grant HIG-133050 from the CIHR in partnership with the Canadian Association for AIDS Research and International AIDS Society. V.S.W. received a CIHR Fellowship. J.-P.R. holds a Louis-Lowenstein Chair in Hematology and Oncology, McGill University.

Authorship

Contribution: V.S.W. generated the majority of results, analyzed data, prepared figures, and wrote the manuscript; A.C. generated results in Figure 6 and significantly contributed to manuscript revision; J.-P.G. performed microarray data analysis and generated figures; D.G. and A.G. performed flow cytometry sorting; A.C.-B. generated results in supplemental Figure 2C; Y.Z. performed experiments; C.L.T. and J.-P.R. ensured access to clinical samples/information and/or provided experimental protocols; P.A. designed research, analyzed data, and wrote the manuscript; and all authors reviewed and accepted the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

ORCID profiles: V.S.W., 0000-0002-4602-4273; A.C., 0000-0001-6741-5145; P.A., 0000-0003-1922-5640.

Correspondence: Petronela Ancuta, CHUM-Research Centre, 900 rue Saint-Denis, Tour Viger R, Room R09.416, Montreal, QC H2X 0A8, Canada; e-mail: petronela.ancuta@umontreal.ca.

References


25. Ancuta P. A slan-based nomenclature for monocytes?


356(6335):eaah4573.

2876 WACLECHE et al 13 NOVEMBER 2018


